Results 121 to 130 of about 154,650 (346)

A Postbiotic‐Inducing Ganoderma applanatum Polysaccharide Repairs the Intestinal Barrier via a Phocaeicola vulgatus ‐ Tridecylic Acid Axis

open access: yesAdvanced Science, EarlyView.
This study identifies GAP2, a bioactive polysaccharide fraction derived from Ganoderma applanatum, as a postbiotic inducer that repairs intestinal barrier damage in a gut microbiota‐dependent manner. GAP2 enriches Phocaeicola vulgatus, which degrades GAP2 and promotes tridecylic acid production, triggering Rho/CDC42 signaling and tight‐junction ...
Chuan Zhang   +10 more
wiley   +1 more source

Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury 1 s⃞

open access: yesJournal of Lipid Research, 2007
Methionine-choline-deficient (MCD) diets that cause steatohepatitis in rodents are typically enriched in polyunsaturated fat. To determine whether the fat composition of the MCD formula influences the development of liver disease, we manufactured custom ...
Gene S. Lee   +4 more
doaj   +1 more source

Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS

open access: yesAdvanced Science, EarlyView.
Lipid stress drives O‐GlcNAcylation of the m6A demethylase FTO at Ser195, enhancing its stability and demethylase activity. This modification removes m6A from HRAS mRNA, preventing its degradation and activating PI3K/AKT signaling to promote hepatic steatosis and inflammation.
Jia‐Xin Yin   +9 more
wiley   +1 more source

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

open access: yesThe Lancet, 2014
Summary Background The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. We assessed the efficacy of
B. Neuschwander-Tetri   +17 more
semanticscholar   +1 more source

Mixed steatohepatitis: more questions than answers (Part 1) [PDF]

open access: yes, 2020
The term steatohepatitis is used for a heterogeneous group of diseases of various etiologies, characterized by a similar morphological picture.
E. A. Kondrashina   +2 more
core   +1 more source

Hepatocyte CBX2 Safeguards Hepatic Lipid Homeostasis by Elevating Ca2+‐CaMKK2‐AMPK Signaling to Counter MASLD

open access: yesAdvanced Science, EarlyView.
In hepatocytes, CBX2 promotes H3K4me3 enrichment at the Orai1 promoter to enhance Orai1 transcriptional activation, thereby increasing intracellular Ca2+ levels. The elevated Ca2+ activates the CaMKK2‐AMPK signaling cascade, resulting in ACC phosphorylation and downstream metabolic regulation. This cascade suppresses de novo lipogenesis (Fasn, Acc, Scd‐
Xiang Wei   +18 more
wiley   +1 more source

Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis

open access: yesAdvanced Science, EarlyView.
A chiral gold nanozyme was coated onto the gut commensal bacterium Faecalibacterium duncaniae (F. duncaniae) to create an engineered probiotic. In mouse models of MASH, this orally administered living therapeutic protected the bacterium against oxidative stress, enhanced its gut colonization, reversed steatosis, inflammation, and fibrosis, and improved
Jing Chen   +12 more
wiley   +1 more source

Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis

open access: yesCell Death and Disease, 2019
Nonalcoholic steatohepatitis (NASH) is a metabolic liver disease that progresses from simple steatosis to the disease state of inflammation and fibrosis.
Shinya Tsurusaki   +11 more
semanticscholar   +1 more source

Non-alcoholic steatohepatitis and liver transplantation

open access: yes, 2016
Non-alcoholic steatohepatitis is a growing liver-related health problem. In Europe, non-alcoholic fatty liver disease is the most usual reason of chronic liver illness while steatohepatitis, its progressive form, affects 1% of Europeans and North ...
Andreone, Pietro   +6 more
core   +1 more source

ADISSP Drives Metabolic Reprogramming and Immune Suppression to Regulate Hepatocellular Carcinoma Progression and Immunotherapy Sensitivity

open access: yesAdvanced Science, EarlyView.
In HCC, ADISSP sustains IKKβ/NF‐κB signaling by inhibiting PPP1CA‐mediated IKKβ dephosphorylation, thereby inducing the expressions of SLC16A3 and CCL20. SLC16A3‐driven lactate remodeling promotes glycolysis, ferroptosis resistance, and M2 macrophage polarization, whereas CCL20 facilitates macrophage recruitment.
Tuan‐Song Zhang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy